Select country set
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

S100A8/A9 (Calprotectin) Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, HRP-labelled antibody
  • Other names:MRP8/14, Myeloid Related Protein 8/14, Calprotectin
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

RD191217100R 96 wells (1 kit)
PubMed Product Details
Technical Data


For processing the stool samples we recommend using BioVendor Extraction Buffer. The reagent is not included and can be ordered separately (Cat. No.: C005821, 100 ml).

Please find the protocol for preparation and analysis of stool extracts in Docs.


Sandwich ELISA, HRP-labelled antibody


Stool, Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate, Urine, Cerebrospinal fluid, Bronchoalveolar lavage

Sample Requirements

Serum, Plasma, BALF, Urine, Stool extract: 5 µl/well
CSF: 35 µl/well
For processing the stool samples we recommend using BioVendor Extraction Buffer. The reagent is not included and can be ordered separately (Cat. No.: C005821, 100 ml).


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

1–64 ng/mL

Limit of Detection

0.22 ng/mL

Intra-assay (Within-Run)

n = 8; CV = 5.0%

Inter-assay (Run-to-Run)

n = 6; CV = 4.2%

Spiking Recovery

Serum: 100.7 %
CSF: 99.4 %
Urine: 90.0 %
BALF: 103.7 %
Stool extract: 90.0 %

Dilution Linearity

Serum: 96.8 %
CSF: 102.5 %
Urine: 97.4 %
BALF: 99.5 %
Stool extract: 110.5 %


  • bovine Non-detectable
  • cat Non-detectable
  • dog Non-detectable
  • goat Non-detectable
  • hamster Non-detectable
  • horse Non-detectable
  • chicken Non-detectable
  • monkey Non-detectable
  • mouse Non-detectable
  • pig Non-detectable
  • rabbit Non-detectable
  • rat Non-detectable
  • sheep Non-detectable
  • human Yes


The antibodies used in this ELISA are specific for human S100A8/A9. No crossreactivity has been observed for other human recombinant S100 proteins such as S100A1, A4, A5, A6, A7, A10, A11, A12, A13, A14, A15, A16, S100B and S100G protein at 200 ng/ml. Determination of S100A8/A9 does not interfere with haemoglobin (0.05 mg/ml), bilirubin (170 mmol/l) and triglycerides (5.0 mmol/l).



  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures S100A8/A9 in human serum, plasma (EDTA, citrate, heparin) bronchoalveolar lavage fluid (BALF), cerebrospinal fluid (CSF), urine samples and stool samples
  • Extraction Buffer (Cat. No.: C005821) needed for extraction of stool samples is not included and can be obtained from BioVendor. For details please contact us at
  • Assay format is 96 wells
  • Quality Controls are human serum based
  • Standard is recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Inflammatory bowel disease


S100A8/A9, also known as calprotectin or MRP8/14, is a heterocomplex of the two S100 calcium binding proteins, S100A8 (calgranulin A or MRP8 – myeloid related protein 8) and S100A9 (calgranulin B or MRP14 – myeloid related protein 14). S100A8 has a molecular weight of 11.0 kDa and S100A9 exists in two forms, 13.3 kDa and truncated 12.9 kDa. Both proteins are similar to other members of the S100 family in that they contain two EF-hand motifs that bind calcium ions. Ca2+-binding induces the formation of heterocomplexes S100A8/S100A9 and (S100A8)2 /(S100A9)2.
S100A8 and S100A9 are expressed in a tissue/cell-specific manner mainly in cells of the myeloid lineage, such as granulocytes, monocytes and early stages of macrophages, but not in resident tissue macrophages. They are also expressed in keratinocytes and epithelial cells but only under inflammatory conditions. S100A8/A9 complex is an antimicrobial peptide that is released by innate immunity cells immediately after host pathogen interaction, protects cells against invasive microorganisms, and regulates adhesion of leucocytes to the endothelium and extracellular matrix during the inflammatory process.
S100A8/A9 has emerged as a very promising biomarker for a wide range of inflammatory processes such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, inflammatory bowel disease (IBD), acute lung inflammation and vasculitis. Fecal S100A8/A9 level reflects the severity of mucosal inflammation and is a good diagnostic marker for monitoring of IBD (Crohn’s disease, ulcerative colitis) and neoplasm. S100A8/A9 serum levels have been identified as independent risk predictors for various cardiovascular diseases such as acute coronary syndrome and myocardial infarction. High circulating levels of S100A8/A9 complex were measured in patients with abdominal adiposity and correlated with visceral fat area, body mass index, subcutaneous fat area, and leukocyte count. S100A8 and S100A9 play a critical role in tumor biology and their elevated levels were found in numerous tumors. In cancer progression low concentrations of S100A8/A9 complexes promote tumor cell growth and tumor cell migration, while high concentrations are associated with apoptotic effects on tumor cells. Measuring urinary calprotectin shows potential in the differential diagnosis of acute kidney injury (AKI).

Product References (1)


  • Khorrami S, Tavakoli M, Safari E. Clinical Value of Serum S100A8/A9 and CA15-3in the Diagnosis of Breast Cancer. Iran J Pathol. 2019 Spring;14(2):104-112. doi:10.30699/IJP.14.2.104. Epub 2019 Jun 10. PubMed PMID: 31528166; PubMed CentralPMCID: PMC6679667. See more on PubMed
Summary References (16)

References to S100A8/A9

  • Altwegg LA, Neidhart M, Hersberger M, Muller S, Eberli FR, Corti R, Roffi M, Sutsch G, Gay S, von Eckardstein A, Wischnewsky MB, Luscher TF, Maier W. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J. 2007 Apr;28 (8):941-8
  • Andres Cerezo L, Mann H, Pecha O, Plestilova L, Pavelka K, Vencovsky J, Senolt L. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther. 2011;13 (4):R122
  • Andres Cerezo L, Mann H, Pecha O, Plestilova L, Pavelka K, Vencovsky J, Senolt L. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther. 2011;13 (4):R122
  • Bealer JF, Colgin M. S100A8/A9: a potential new diagnostic aid for acute appendicitis. Acad Emerg Med. 2010 Mar;17 (3):333-6
  • Bhardwaj RS, Zotz C, Zwadlo-Klarwasser G, Roth J, Goebeler M, Mahnke K, Falk M, Meinardus-Hager G, Sorg C. The calcium-binding proteins MRP8 and MRP14 form a membrane-associated heterodimer in a subset of monocytes/macrophages present in acute but absent in chronic inflammatory lesions. Eur J Immunol. 1992 Jul;22 (7):1891-7
  • Chen YS, Yan W, Geczy CL, Brown MA, Thomas R. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther. 2009;11 (2):R39
  • Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, Hashemi M, Wesselborg S, Kerkhoff C, Los M. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol. 2008 Jun;83 (6):1484-92
  • Heller F, Frischmann S, Grunbaum M, Zidek W, Westhoff TH. Urinary calprotectin and the distinction between prerenal and intrinsic acute kidney injury. Clin J Am Soc Nephrol. 2011 Oct;6 (10):2347-55
  • Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ, Zinsmeister AR. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 2000 Oct;95 (10):2831-7
  • Lood C, Stenstrom M, Tyden H, Gullstrand B, Kallberg E, Leanderson T, Truedsson L, Sturfelt G, Ivars F, Bengtsson AA. Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus. Arthritis Res Ther. 2011;13 (2):R60
  • Mortensen OH, Nielsen AR, Erikstrup C, Plomgaard P, Fischer CP, Krogh-Madsen R, Lindegaard B, Petersen AM, Taudorf S, Pedersen BK. Calprotectin--a novel marker of obesity. PLoS One. 2009;4 (10):e7419
  • Striz I, Trebichavsky I. Calprotectin - a pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004;53 (3):245-53
  • Terrin G, Passariello A, Manguso F, Salvia G, Rapacciuolo L, Messina F, Raimondi F, Canani RB. Serum calprotectin: an antimicrobial peptide as a new marker for the diagnosis of sepsis in very low birth weight newborns. Clin Dev Immunol. 2011;2011:291085
  • Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002 Aug;123 (2):450-60
  • Vogl T, Roth J, Sorg C, Hillenkamp F, Strupat K. Calcium-induced noncovalently linked tetramers of MRP8 and MRP14 detected by ultraviolet matrix-assisted laser desorption/ionization mass spectrometry. J Am Soc Mass Spectrom. 1999 Nov;10 (11):1124-30
  • Yong HY, Moon A. Roles of calcium-binding proteins, S100A8 and S100A9, in invasive phenotype of human gastric cancer cells. Arch Pharm Res. 2007 Jan;30 (1):75-81
Related Products Docs